INFORMAZIONI SU
MALLOZZI Jacopo Maria
 |
Supervisori: Dr. Baldassare,Dr.ssa Schiappacassi, Dr.ssa Spessotto e |
| Among ovarian cancers, epithelial ovarian cancer (EOC) is the most common and deadliest type. A major challenge in treating EOC is the high rate of recurrence and the development of resistance to the most common platinum-based chemotherapy drugs. Understanding the molecular mechanisms of this chemoresistance is critical for developing effective EOC treatments. Our laboratory at CRO of Aviano identified SGK2 (Serum-and Glucocorticoid-inducible kinase 2), a kinase protein, as a potential modulator of platinum sensitivity. Therefore, we aim to elucidate the molecular mechanisms and genetic alterations by which SGK2 contributes to chemoresistance and tumor progression. To achieve this, we will utilize different EOC cellular tools generated through CRISPR Cas9 technology to investigate SGK2's activity in vitro and in vivo using xenograft models. Finally, we will assess the clinical relevance of SGK2 by analyzing a large collection of primary tumor and cell samples collected within our institute. | |